Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston

Wednesday, June 28, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

LUND, Sweden, June 28, 2017 /PRNewswire/ --

Immunovia (IMMNOV) today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized. This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilities for commercialization, covering marketing, sales and customer support.

 

A highly skilled team with a proven track record of successfully establishing and scaling up CLIA accredited reference laboratories based on ground breaking new technologies have been recruited to carry out the US market introduction

of Immunovia's first test, IMMray™ PanCan-d, in the second half of 2018.

Mats Grahn, CEO Immunovia, comments: "The market introduction of IMMray™ PanCan-d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia. We have therefore chosen to establish our USA operations headquarters in Boston, which is the major biotech hub in the world. A very experienced laboratory team will be moving into Immunovia´s own reference laboratory that will cover Eastern USA, adding to our commercial group that will also be located at the Boston facilities. This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA."

About Immunovia  

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: http://www.immunovia.com )

Immunovia's shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company's Certified Adviser.

For more information, please contact: Mats Grahn Chief Executive Officer, CEO, Immunovia Tel.: +46-70-5320230 Email: [email protected]

SOURCE Immunovia



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook